Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx Receives European Patent For Arimoclomol
CytRx has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate –
CytRx has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate –
Merck has updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the company’s investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent
Quintiles has reported a strategic alliance agreement with the University of Pretoria as part of its Prime Site program, an initiative to accelerate the development of new and
StemCells has reported that it will soon initiate, along with the University of California, San Francisco (UCSF) Children’s Hospital, a phase I clinical trial to evaluate the therapeutic
Generex Biotechnology (Generex) has reported that the FDA has granted approval for its Oral-lyn under the FDA’s Treatment Investigational New Drug (IND) program. Reportedly, the drugs that are
Pluristem has started enrolling patients in the US for a phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the company’s lead product candidate for
Centocor Ortho Biotech has received a Complete Response Letter from the FDA regarding the New Drug Application (NDA) for trabectedin, when administered in combination with DOXIL (doxorubicin HCI
Mpex Pharmaceuticals (Mpex) has reported positive data from its phase 2b clinical trial with Aeroquin (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Reportedly, the
Access Pharmaceuticals has provided an update on its clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor
Scarab Genomics has entered into a license agreement with NeoClone to market and distribute their antibodies against Shiga toxin. This toxin is secreted by E. coli bacteria, which